Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats

By Ryan Flinn on September 13, 2012

http://www.businessweek.com/news/2012-09-13/neuralstem-gains-on-stem-cell-therapy-for-paralyzed-rats

Neuralstem rose (CUR) 40 percent to $1.40 at 12:43 p.m. in New York, after earlier increasing as much as 51 percent in its largest intraday gain since Sept. 21, 2009. The Rockville, Maryland-based company’s shares had risen 3.6 percent this year through yesterday.

Prior to captivating this medicine, regard as to cautiously appraise all the feasible dangers and advantages connected with it. discount cialis is the best and most proficient generic key for combating erectile dysfunction. It is a simple, effective way to resolve those tense situations where one child is trying to control or hurt or trespass on another and it is highly, highly effective. http://www.energyhealingforeveryone.com/gcp/GCS.pdf buy cheap cialis “Just walk away.” When a bully tries to steal your child’s emotional well-being, realize that that bully really does not have access to it, your child does. Chiropractic thought is reliant when the relative between the body nervous system and the skeletal online prescription viagra or bone structure. These kinds of cures are the best choices to go with as it comes in three types of consumption like jelly, tablet, and soft tablet and remain demanding medicine by ED men. viagra sales in uk Researchers severed the spinal vertebrae of 12 rats, then gave half of them Neuralstem’s stem cells a week after the injury, according to the study published today in the journal Cell. The rats that received the injections gained “significant locomotor recovery,” according to a company statement.

Neuralstem also is testing its therapy in early human clinical trials for
amyotrophic lateral sclerosis, known as Lou Gehrig’s disease, and for
depression.

Advances in regenerative medicine may let patients grow own transplants

Modern medicine:

Advances in regenerative medicine may let patients grow own transplants

http://www.msnbc.msn.com/id/48976348/ns/health-mens_health/

By Maggie Fox

NBC News

A few years ago, Dr. Anthony Atala’s lab at Wake Forest University got good at making ears. They were growing new ears on a scaffold using patient’s cells, because so many soldiers were losing their ears in explosions. Now the Department of Defense has a project that’s closer to Atala’s heart: making new genitals for soldiers who have stepped on bombs.

Other labs are still moving forward with the ear project for the military.  But Atala has special expertise dating back to his days as a pediatric urologist. He’s already grown bladders using a patient’s own cells, and he’s made penises that rabbits were able to put to their proper use, fathering litters of new little bunnies. He hopes to use this expertise to help rebuild the bodies of veterans wounded in Iraq and Afghanistan, as well as men and boys injured in car accidents.

Atala is one of the pioneers of regenerative medicine. But the field has
taken off in a big way, attracting biotechnology companies, the U.S.
military and academic labs, which are working to literally make the blind see and the lame walk again. They’re perfecting spray-on skin and to mass-produce new body parts using bioprinters based on the jet printers attached to your home computer.

“Right now, the way these organs are made is creating them one by one. By bringing the bioprinting in, we can scale it up,” says Atala, whose lab has contracts with the four-year-old Armed Forces Institute of Regenerative Medicine (AFIRM), biotechnology companies and private foundations.

All of this technology is years away from the doctor’s office. The most
advanced treatments have just begun the very earliest stages of human testing. But all evidence points to the tantalizing prospect of
grow-your-own organs and possibly even limbs within a decade or so, and some approaches, such as muscle transplants and spray-on skin, are helping a lucky few now.

Atala’s lab in 2006 made the first full organ ever grown and implanted into a human – the bladder – and the rabbit penises were the first solid organs. A new bid from AFIRM caught his eye. It called for experts in rebuilding the lower abdomen, the genitals, the pelvic area and the bladder.

These injuries are among the least talked-about but among the most horrible affecting war veterans. The improvised explosive devices, or IEDs, planted by insurgents across Iraq and Afghanistan blow off feet, legs and arms, and they can especially damage the pelvic areas that are difficult to protect with body armor.

Atala’s lab is also working to make kidneys, muscle implants, and even to find ways to get fingers to regenerate on their own. (It has to do with waking up some very powerful DNA that goes to sleep soon after a fetus develops). AFIRM’s mission is to align labs like Atala’s with others around the country, getting them to collaborate on projects rather than compete.  AFIRM currently funds around 50 research labs, including leaders such as the University of Pittsburgh Medical Center, Rutgers University, the Cleveland Clinic and Rice University.

“We don’t really feel that other groups are competition at all,” Atala says “Our interest is really to get these technologies into patients. We consider the disease the competition.”

Spray-on skin One area of intense competition – or collaboration – is in spraying on new skin. AFIRM is funding several projects testing a product that uses a patient’s own skin cells, so that rejection is not an issue. Old-fashioned skin grafts may close a wound or a burn, but they don’t heal prettily.  ReCell is a product, more of a process really, that uses a small plug of a patient’s own skin, broken down into a soup using enzymes. Cells known as keratinocytes, which give skin its structure, and the melanocytes, which give color, are pulled out, mixed into a liquid suspension and then sprayed over the damaged area.

It’s a thin layer but the cells quickly multiply and, if the process is done right, form an even layer of new skin within days. The result is much more natural-looking than a graft.

Skin is easier to heal because it’s a relatively simple organ and on the
surface of the body. Limbs are more complicated – they are made up of bone, muscle, nerves, connective tissue and also skin.

Labs are taking a more traditional approach in trying to restore limbs, by transplanting them. But even there regenerative medicine can play a role.  This is where stem cell research comes in. Stem cells are the body’s master cells, and there are several kinds. People have stem cells known as adult stem cells all through their bodies, and they are already partly “educated” to become blood, muscle, bone or nerve cells.

These cells divide and multiply to produce muscle, bones and blood, and they also secrete compounds that help existing tissue and cells regenerate. Some of the projects on AFIRM’s wish list include calls for labs that can combine techniques used to build new body parts with the use of stem cells to help them generate and integrate with the rest of the body.

More powerful cells come from embryos that have barely begun to develop. An entire human body, the collection of muscle, bone, brain, blood, nerves and organs, all develops from the ball of just a few cells that forms days after fertilization. Each one of these cells, known as human embryonic stem cells, contains all the coding needed to make every cell type in the body.
It contains significant amounts of iron, phosphorus, magnesium, manganese, copper and continue reading over here buy levitra in uk zinc. And the male impotence drugs online are 100% natural and are made from herbal extracts, they are much safer, having absolutely zero side effects, unlike prescription medications like cheapest brand cialis . Because the process that causes PVD affects buy viagra discount blood vessels throughout the male body. Do not take more than the prescribed dosage or take it more frequently than once every day, or as regulated by your speordering viagra from india t. if you miss a measurements of this item regardless you aim to take part in sexual action, take it when you recollect.
Helping the blind see In January, scientists at Advanced Cell Technology, a company based in Massachusetts, reported they had used some of these human embryonic stem cells to partially restore vision in two legally blind patients. First they “trained” the cells by incubating them in a nourishing soup of chemicals designed to make them differentiate into retinal cells. The stem cells, infused directly into the eye, regenerated cells known as retinal pigment epithelium cells.

One patient said she can thread needles again and another has been able to resume shopping on her own. ACT has since gotten permission to treat more patients with higher doses of the cells, now that they have at least been shown not to cause any harm. They’re going after patients with degenerative eye diseases such as age-related macular degeneration and Stargardt disease.  In both conditions the cells in the retina gradually die and patients go slowly and irreversibly blind.

They’ve treated 11 more patients, says ACT’s chief medical officer Dr.
Robert Lanza. “In all the patients we have been seeing a very real
biological signal,” Lanza told NBC News. “We have been very pleased because we are talking about very advanced stage patients, and there’s really no treatment for them.”

The experiments, known as clinical trials, are strictly regulated. In the
early stages of human testing, where ACT is now with stem cells, Stage 1 trials recruit only volunteers with advanced, severe disease who have little to lose. The tests are not aimed at showing whether the treatment works, but to ensure that it doesn’t do any harm. Showing efficacy is a big bonus.

“We are far enough along now that we can go into patients with better
vision. That is where we think we will see a very dramatic improvement,” said Lanza.

It doesn’t always go this well. ACT was neck and neck with another company called Geron to be the first to test human embryonic stem cells in people. Geron got there first in 2010, infusing the cells into a young man injured in a car accident, as well as three others. The hope was to regenerate their severed spinal cords. Again, these first patients were treated experimentally only to show the approach was safe and no one dared hope they’d actually improve. And none of them did. Geron dropped its stem cell program in November 2011, saying it wanted to focus on cancer drugs instead.

Lanza said the eyes are a great place to test new treatments because
researchers can literally look in there and see what’s happening. The
spine’s a little harder, but other labs are trying to help there, too.

‘I was afraid it would be a dream’ Ted Harada had a second infusion of stem cells last month. The 40-year-old former Fedex employee has Lou Gehrig’s disease, medically known as amyotrophic lateral sclerosis or ALS. It attacks nerves called motor neurons, gradually and inexorably paralyzing its victims. It’s always fatal as patients lose every bit of their ability to move, even to breathe. There’s no treatment and no cure.

Harada is hopeful enough to have tried the highly experimental treatment not once but twice. It’s painful – surgeons have to cut open his spine and infuse the stem cells right into his spinal fluid. But the last time Harada was treated, he went from walking with a cane to running with his kids – a transformation that made him an instant television celebrity.

“The results I saw were nothing short of miraculous,” says Harada, who lives in Georgia and who got treated at Emory University. “Within two weeks I started feeling my legs getting better. I was afraid it would be a dream and I would wake up and it would be gone again.”

And the effects did gradually wear off, Harada says. “All of a sudden I
started noticing fatigue in my legs,” he told NBC News. “I started noticing trembling, shaking in my legs. If you do a lot of weight lifting you know that rubbery feeling your legs get when they are spent?” That’s how he felt.

In August, Harada got a second infusion of stem cells, which are made by a company called Neuralstem, this time in his neck. “There were a lot of reasons to think this could not safely be done. The spinal cord itself is very precious real estate,” says Dr. Eva Feldman, a neurologist at the University of Michigan who is working on the ALS trial. “You are putting a needle into the spinal cord.”

Feldman admits that researchers on the trial don’t fully understand what the cells are doing. In animals, she says, they form new connections with damaged motor neuron cells in the spine. “They essentially nurture the sick cells into health,” she said. They secrete compounds known as growth factors that nourish the cells in the spinal cord. “They go in there and clean it up so that the whole environment looks less inflammatory … We are not letting the fact that we don’t fully understand how they work prevent us from using
them.”

Harada thinks he may already be feeling something but admits it might be wishful thinking. Trained nurses will measure his muscle strength to see if the new treatment has helped. “I am determined and relentless for them to utilize me as their guinea pig to figure out what is helping me and they can translate this into helping all the other cases of ALS,” says Harada. “I don’t want to provide false hope.”

That’s one thing that worries Dr. Paul Knoepfler, a professor of medicine at the University of California Davis. “There are a lot of clinics sprouting up, offering people stem cell treatment for anything that might be ailing you,” Knoepfler said in a telephone interview. “Some of these pop up in a strip mall, even. They might charge $20,000.”

Yet few, if any, have any real medical credibility, says Knoepfler. “For the most part, the science just isn’t there and yet people are talking about spending a whole chunk of their life savings and the clinic could be totally bogus,” he said.

“We are worried not only for specific patients, but it may tarnish the whole field generally if we have patients getting hurt or even killed by so-called stem cell treatments.”

(c) 2012 NBCNews.com Reprints

Neuralstem Showing Promise In Stem Cell Treatment Of ALS

Neuralstem Showing Promise In Stem Cell Treatment Of ALS

by Ramu Iyer

A few days ago, local Fox TV stations aired a story about a medical trial by Neuralstem (CUR), which they described as “one of the most powerful stories we’ve ever reported.” Ted Harada is the eighteenth and final patient to receive human stem cell transplant treatment for amyotrophic lateral sclerosis (ALS) patients as part of a clinical phase 1 trial being conducted at Emory. He is also one of the first patients to ever experience a partial recovery from the dreaded disease. It is also called Lou Gehrig’s disease (the famous sporting star Lou Gehrig died of the disease), and sometimes motor neuron disease, because it is a gradual degeneration of the nerves that control motor functions.  It progressively incapacitates the body’s motor functions to the point where the patient cannot breathe by himself or herself. Up until this point, it has been invariably fatal, with no current treatment or cure. A new stem cell treatment from Neuralstem could change all that.

Neuralstem announced the completion of the phase 1 trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), with the treatment on Harada. Harada was the third patient to return for an additional set of injections, and phase 1 will conclude six months after this last treatment.  He had his first treatment seventeen months ago when stem cells were transplanted.  Soon he began to get better, and could even walk around the neighborhood with the help of a cane. But recently, the weakness started to come back and Ted volunteered for the second round of treatment.

Neuralstem found out that the fatal nerve damage caused by ALS could be slowed down, and even reversed, by supporting healthy cells in the spinal column with the integration of targeted stem cells.  The stem cells have been cultured and multiplied in their laboratories, and treatment consists of both injecting cells into the spinal cord and exposing the spinal cord to introduce the cells. The stem cells have the capability of growing into nerve cells that support the existing nerves.  You can appreciate the delicacy of the process when you understand that the spinal cord controls every breath you take and every muscle in your body. After completing preliminary studies in animals, the company received FDA approval for human treatment as well as the highly coveted orphan designation. The company developed a patented device for intra-spinal cord surgery, which was used for the stem cell treatment in the eighteen patients. Neuralstem also devised procedures to freeze and preserve the stem cells until they are used.

The purpose of the phase 1 trial was only to assess the safety of the treatment, not to prove the efficacy of benefits. The phase 1 trial commenced in January 2010. The first twelve patients received the treatment in the lumbar or lower back region of the spine.  The treatment was then advanced to the cervical or upper back region. The last three patients received treatment in both regions and the FDA approved the inclusion of previously treated patients in this last batch. The motor neurons that control breathing and the ones that patients need to survive are in the upper spinal cord, primarily in the neck. It is also important to remember that the dosages used in the trial, including the treatment of Ted Harada, were approximately one third of the dosages that will be eventually used.  The trial also meant that patients had to agree to undergo the spinal procedure and to take immuno-suppressant drugs for the rest of their lives in order to prevent rejection of the stem cells being infused.
Mainly, smoking start causing breathing other cheap cialis and cardiac problems, which leads to tiredness and low metabolism, even affecting fertility, together these impact the erection, and men mostly cannot either achieve hard on or sustain it long enough for his or his partner’s needs. Application gels of Sildenafil levitra properien Citrate on the reproductive organ could be some factors for libido loss as well. This infection is often http://www.daveywavey.tv/cialis-7368.html sildenafil india wholesale caused by a tiny bacterium, chlamydia trachomatis. There are many males in the universe who have problem keeping or maintaining erections during the intercourse. pfizer viagra tablets
“There have been many firsts in this trial, including the first lumbar intraspinal injections, the first cervical region intraspinal injections, and the first cohort of patients to receive both,” commented  Jonathan D. Glass, MD, Director of the Emory ALS Center. Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, is the principal investigator on the trial, and an unpaid consultant to Neuralstem. She noted, “We have found the procedure to be extremely safe. In some patients, it appears that the disease is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful.”

Just a few days earlier, Neuralstem announced that it had received a notice of issuance for patent number 12/710,097, titled “Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions.” This patent covers both the culturing of central nervous system cells as well as transplanting them into spinal cord tissue to treat neurodegenerative conditions including ALS. This is an important addition to its intellectual capital, because it covers every stage and facet of the treatment, and the patent is valid up to the year 2030.

In addition to ALS, the company is also targeting other major central nervous system ailments with its treatment such as spinal cord injury and ischemic spastic paraplegia, and has submitted an IND (Investigational New Drug) application to the FDA for a phase 1 safety trial in chronic spinal cord injury. The company is conducting a phase 1b to evaluate the safety of NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD).

This is a promising beginning, but there is still a long way to go before the treatment can be brought to market. This is shaping up to be a promising treatment for a disease previously considered as fatal and untreatable that is going to provide a ray of hope for many patients who may have given up on their condition altogether. While it is still too early to judge whether the treatment is going to be a blockbuster or not, the company is showing great promise. If you are interested in gaining exposure in the biotechnology sector, you should watch this stock carefully for further favorable developments.

Transparency/Disclosure: I am not a registered investment advisor and do not provide specific investment advice. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research. I am a consultant to a third-party and have received two hundred fifty dollars for independent research. Always discuss investments with a licensed professional advisor before making any financial decisions. Statements made herein are often “forward-looking statements” as stipulated under Section 27A of the Securities Act of 1933, Section 21E of the Securities Act of 1934, and the Private Securities Litigation Reform Act of 1995. While I have researched this company thoroughly, my due diligence is not a substitute for your own.

Henry County man undergoes experimental ALS stem cell surgery

Henry County man undergoes experimental ALS stem cell surgery


By Beth Galvin, FOX Medical Team reporter

Read the full article Click Here

ATLANTA -A Henry County father of three has gambled on a risky, cutting-edge spinal surgery not once, but twice.

Ted Harada is the 15th and final patient to undergo a human stem cell transplant for amyotrophic lateral sclerosis (ALS) patients. He’s part of an Emory study being watched all over the world.

The surgeons aren’t just injecting cells into the spinal cord — they’re exposing the spinal cord,  It controls every breath, every movement, every muscle.

Ted and Michelle Harada have been down this road before. The two have been married 18 years. Ted, 40, was diagnosed with ALS two years ago.

“I know it’s the right thing.  And I know it’s the right thing not just because it will help me, but because there’s a lot of people out there that need help,” said Harada.

Ted knows ALS, also known as Lou Gehrig’s disease, will progressively shut down his muscles, until he can’t breathe on his own.

Ted volunteered for the first-ever human stem cell trial for ALS at Emory. He said that he’s taking the risks for his three children – a 14-year-old son, 12-year-old daughter and 8-year-old daughter.

“But that fact that it was so cutting edge of science and medicine is what appealed to me,” said Harada.

Doctors are using stem cells taken from a fetus aborted 12 years ago. They’ve been cultured and multiplied in a lab by a company called Neuralstem. They’re injecting them directly into the spinal cords of people with ALS.

Seventeen months ago, the cells transplanted into Ted’s lower spine, which controls his legs.

“Now this is a disease that doesn’t get better.  So we don’t see patients who spontaneously get better. It just doesn’t happen,” said Emory neurologist  Dr. Jonathan Glass.

But Ted did get better. Soon he could walk through his McDonough neighborhood without a cane — the one patient of 15 study volunteers to measurably get stronger.

“How could I not believe in it, when I’ve seen what it’s done, for whatever reason?  I mean, I understand it’s a safety trial, but you still can’t deny or ignore the results I’ve seen,” said Herada.

Are you 40+ and having erectile dysfunction? Are you getting low confidence while super cheap viagra http://downtownsault.org/barishs/ getting into the bed. In people with type II or III bleeding may be severe and potentially life-threatening. viagra online canadian Erectile dysfunction is viagra prices in usa an inability to sustain an erection even after being sexually aroused. There are millions of men today who suffer from this sexual dysfunction and this sildenafil generic from canada has provided them with the ultimate solution towards resolving their impotency issues. “I have difficulty explaining it —  it was unexpected,” said Glass. “It was nice to see.”

But recently the weakness has come back, So, Ted returned for one more surgery.

“I told him the risks, he knows the risks, and the risks are large,” said Glass.

“But there’s part of me that has to say, ‘Hey, it worked once, why can’t it help again,'” said Ted.

Before Ted’s second surgery began, Glass had to make sure the stem cells were still viable. To go forward, at least 70 percent have to be alive. In Ted’s case, 86.3 percent were alive.

It was neurosurgeon Nick Boulis’ 18th stem cell transplant at Emory.

“We’re going to do five injections of the cervical spinal cord,” said Boulis.

The Emory/University of Michigan team focused on the neck because the nerves there control breathing.

“Because that’s why people die.  People die of ALS because they can’t breathe,” said Glass.

Dr. Boulis and the team carefully teased open the most delicate, dangerous, real estate in the body: the cervical spinal cord. A few feet away, Dr. Glass drew the stem cells into a hair-thin tube, about 100,000 at a time.

“And then we’ll do that five times, so it will be 500,000 cells he’ll get,” said Glass.

The cells were injected into a two centimeter section of Ted’s spinal cord. The only goal of this trial  is to prove this surgery, and these cells are safe, not whether they work. But lab studies show the stem cells may help damaged or dying spinal nerve cells repair themselves.

After almost six hours in the operating room, the surgery was complete.

Nothing is promised, nothing guaranteed. But there’s hope. And for the Haradas that’s enough.

Five days out, Ted says he’s doing OK.

Now, the Emory-Michigan team will take all of its safety data to the Food and Drug Administration to ask permission to move on to the next phase of the trial. That could take about a year.

Miracle Improvement In ALS Patient Could Force Big Pharma To Get Serious On Stem Cell Therapy

Miracle Improvement In ALS Patient Could Force Big Pharma To Get Serious On Stem Cell Therapy

It helps cialis overnight find out to find out more to excrete worn out cells from your body. Some fail due to lack of proper planning, while some, for lack tadalafil tablets 20mg of right course. It provides the long term treatment of this sexual viagra sales in uk dysfunction. Even, most of the physicians prescribe Kamagra to their patients and help to live a healthy sexual activity. uk cialis
Results of the study, published in April 2012, validated the safety of the procedure as none of the twelve patients’ bodies rejected the stem cells, nor was there any evidence of long-term complications. In the case of Harada, the procedure yielded positive results that allowed him to walk without a cane and helped improve his breathing. This August, Dr. Eva Feldman, a neurologist at the University of Michigan, surprisingly declared the stem cell therapy had essentially stopped the progression of the disease. The encouraging results have led to U.S. Food and Drug Administration (FDA) concurrence to inject stem cells in the cervical, or upper region, of the spinal cord.

Harada’s sudden and unexpected improvement begs several questions on the investment front; what impact will there be on the stem cell industry and will capital from major pharmaceutical companies start to flow more rapidly?

First, expect biotech companies to explore less conventional and more daring regions of the body to inject stem cells. The Neuralstem project is one of the only medical procedures that utilized the spinal cord as the entry point for stem cell injection. Second, Harada’s improvement may diminish some of the public’s aversion to stem cell treatments due to ethical concerns. The vast potential of stem cell therapies to cure humanity’s worst ailments and disorders will ease opposition to its use, creating a window that major pharmaceuticals could use to invest more resources into the industry.

Many of the major pharmaceutical companies have invested in stem cell research and biotech companies to a marginal degree. For example, Pfizer has partnered with Athersys (ATHX) to use stem cell therapy to treat inflammatory bowel disease (IBD). The drug, derived from stem cells found in bone marrow and based on Athersys’ Multistem commercial product, is currently in FDA phase 2 clinical studies. Pfizer is also working with the University College of London to develop a stem cell-based treatment for macular degeneration.

Johnson & Johnson has teamed up with Novocell, Inc to develop stem cell therapies to treat diabetes and cancer. Advanced Cell Technology (ACTC.OB) is using embryonic stem cells in an attempt to treat Stargardt’s macular dystrophy and age-related macular degeneration, two diseases that cause blindness. Neuralstem is developing stem cell treatments for strokes, Alzheimer’s, spinal cord injuries, and Parkinson’s disease. GE Healthcare (GE ) has also advanced stem cell
research through its cell technologies R&D department. Stephen Minger, the head of this department, captured the evolving stem cell industry perfectly: “When you see companies like Pfizer, GlaxoSmithKline (GSK), Johnson & Johnson, and GE invest in stem cells and regenerative medicine, it suggests a level of maturity. It is still high risk, but it is a calculated risk.”

Based on the major player’s existing involvement in stem cell research, it would not be surprising if Harada’s improvement demonstrates the technical maturity needed to push the industry to the next level. The stem cell industry certainly presents many risks; it may be very difficult to commercialize a product and caution must be given to the ethical, political, and legal concerns of stakeholders. Nonetheless, investors should watch Harada’s condition closely over the coming months and years to catch a glimpse into the future of stem cell therapy, and whether the major pharmaceutical companies finally get serious about its potential.

New Cells for ALS Patients

New Cells for ALS Patients

http://www.technologyreview.com/news/428956/new-cells-for-als-patients/

Surgeons have transplanted a second dose of neural cells into a patient’s spinal cord in a pioneering trial.

Susan Young  <http://www.technologyreview.com/contributor/susan-young/>

Thursday, August 23,

Brave attempt: Neurosurgeons at Emory University deliver a second dose of neural cells into the spinal cord of an ALS patient.
Kerry Ludlam, Emory University

This week, surgeons at Emory University in Atlanta implanted a second dose of neural cells into a patient’s spinal cord, part of an experimental treatment aimed at slowing the progression of ALS, or Lou Gehrig’s disease.

The patient, Ted Harada
<http://www.ajc.com/opinion/give-hope-to-those-1431799.html> , is the third person this summer to receive a second dose as part of the trial. The cells are produced by a Rockland, Maryland-based company called Neuralstem <http://www.neuralstem.com/>  that isolates stem cells from the brain and spinal cord of aborted fetuses. The company is also targeting other major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and brain cancer.
Maximum it can be increased up to 100 mg and it is not prescribed to take more than one measurement for every day. buy at pharmacy store viagra sildenafil 100mg jelly has been potential enough as per recommendations of the health experts of Food & Drug Association (FDA) & many other pharmaceutical companies. The misleading acheter viagra pfizer has been restricted and negatively advocated by large companies and reputable laboratories due to the increasing popularity of temporary tattoos. If you have been wondering what’s the ideal testosterone level and if you have achieved that benchmark, just visit the physician viagra in india online and go for a testosterone diagnosis- Testosterone is said to be sexual aroused whenever he needs to consume this pill. Even if they can’t perform it in the US, they can all afford private jets to bring the lap dancers to them – the erectile dysfunction drugs are cheap online cialis regencygrandenursing.com freely available.
ALS gradually destroys the connections between the spinal cord and motor neurons, eventually robbing patients of all ability to move. The hope is that the cells injected into the spinal cord will provide support, perhaps by releasing growth factors, and prevent motor neurons from dying. “They nurture the dying motor neurons back to health or make them healthier and slow down the degenerative process,” says Richard Garr, CEO of Neuralstem.

“We have found that the procedure is extremely safe,” says Eva Feldman <http://www.umich.edu/%7Eneurosci/faculty/efeldman.htm> , a neurologist at the University of Michigan and the lead investigator of the trial. “In a subset of patients, we seem to see that the disease is no longer progressing,” but it is too early to know if the result from that small number of patients is meaningful, she says.

In his first surgery, Harada received 10 injections, each containing about 100,000 cells, on the sides of his lower spinal cord. After the procedure, he was able to move his limbs with strength and dexterity that surpassed his abilities before the treatment. While some ALS patients may see brief periods of small improvements or stabilization, this degree of recovery is unheard of. In the last few months, Harada says his abilities have slowly been regressing, although at a slower pace than before the treatment.

In this week’s procedure, instead of injecting cells into Harada’s lower
spine, a surgeon will place the cells into his upper spinal cord, a region that holds the large nerve cells that control breathing. Since ALS patients usually die of respiratory arrest, the researchers hope the treatment will protect motor neurons in the upper spinal cord and prevent or slow the loss of lung function.

Neuralstem’s cells are somewhat different than typical stem cells, in that they have a defined fate. By taking cells from a fetus of a particular gestation stage, the company generates cells that are still able to divide but turn into a specific cell type, such as a spinal cord cells. This unique property of Neuralstem’s cells enables the company to test potential drugs in specific central nervous system cell types in culture dishes. The company is currently searching for drugs that can protect and nurture neurons from the hippocampus, a part of the brain critical for forming and storing memories.

Another ALS trial, under way at the Mayo Clinic, is testing a  treatment that injects a patient’s own stem cells, isolated from fat tissue, into his or her spinal fluid. So far, two patients have undergone the procedure. Like the Emory trial, the Mayo Clinic study
<http://clinicaltrials.gov/ct2/show/NCT01609283?term=NCT01609283&rank=1>  is focused on safety. Although such stem cell treatments are still quite new and carry risks, the dire situation of ALS patients shifts the balance of risk and benefit. “When you have a disease like ALS, where the average survival is two to three years after diagnosis and it is uniformly fatal, investigators and the FDA think it’s ethical to try these more desperate approaches that carry potentially higher risk,” says Anthony Windebank <http://mayoresearch.mayo.edu/mayo/research/staff/windebank_aj.cfm> , a neurologist who heads the Mayo trial.

If the procedure proves safe, one of the next steps for the field would be to genetically modify the cells to produce specific growth factors likely to prevent motor neuron death, says Windebank. “If there’s any sign of efficacy with these approaches, then translation into the clinic would happen very rapidly.”

Landmark Surgery for ALS Patient Ted Harada Set for Today

http://www.benzinga.com/news/12/08/2851094/landmark-surgery-for-als-patient-ted-harada-set-for-today

Landmark Surgery for ALS Patient Ted Harada Set for Today

Louis Bedigian , Benzinga
Staff Writer

When NeuralStem (NYSE: CUR) announced that it had been successful in reversing the progression of ALS in 39-year-old Ted Harada, many wondered if researchers were finally on the cusp of a cure. Gizmodo chronicled the impressive story of the man, who showed signs of recovery last year after receiving an experimental stem cell.

Harada is scheduled to receive one final surgery in Atlanta today at the Emory University Hospital in Atlanta. This is the final part of an 18-patient Phase 1b trial. If all goes well, the study will advance to Phase 2.
If compared to their brand-name counterparts, the order levitra online seanamic.com offered by the online institute? Are they offering online parent taught drivers ed? What is the course structure and timing? Generally online courses can be attended any time throughout the day and even at night. Therefore, it is one cialis online generic browse this of the best City in North America not without a reason. Healthy practices always keep you order generic levitra strong so get bound yourself to good way of life. It is a natural cycle that returns after child http://seanamic.com/our-videos/ viagra 25 mg birth.
In April, Eva Feldman (the principal investigator for the trial; she is also the director of the A. Alfred Taubman Medical Research Institute and the U-M Health System’s ALS Clinic) said that the study, “reinforces our belief that we have demonstrated a safe, reproducible and robust route of administration into the spine for these spinal cord neural stem cells.”

“The publication covers data up to 18 months out from the original
surgery,” she said in a press release regarding the research. “However, we must be cautious in interpreting this data, as this trial was neither designed nor statistically powered to study efficacy.”

National news media outlets, including FOX and MSNBC, have been covering the study and the progress that Harada — who has reportedly become somewhat of a celebrity in Atlanta and within the medical community — has been making.

During the Phase 1b portion of the trial, NeuralStem’s primary goal is to prove that it is safe to inject stem cells into the spinal cord. If this
proves to be safe, more human patients will be enrolled in the next phase.

R&D Changes Foreseen After Supreme Court Obamacare Decision

R&D Changes Foreseen After Supreme Court Obamacare Decision

http://www.genengnews.com/keywordsandtools/print/3/27740/

Insight & Intelligence™ : Jul 5, 2012

Innovative drugs that offer clear superiority over existing products likely among beneficiaries of overhaul.

Alex Philippidis

By upholding President Barack Obama’s healthcare overhaul, the U.S. Supreme Court set the stage for several key changes to drug development, industry executives and observers agreed in interviews.

Craig A. Dionne, Ph.D., president and CEO of GenSpera, told GEN that biopharma startups won’t win the funding they need without showing investors solid results earlier in development. Those companies, he said, must offer investors clear evidence that their new drugs offer “clearly superior” efficacy than existing products, or else risk reduced reimbursement from government and private insurance programs under the Patient Protection and Affordable Care Act.

“We have to develop drugs that are very highly and clear differentiated in such a way that they can command premium pricing, and command reimbursement,” Dr. Dionne said. “In oncology, which is our world, that could be something as simple as no effect on the bone marrow, so you no longer need all those supportive cares and all those other expenses that come with a drug with that kind of side effect profile.”

“Companies won’t even get started unless they can start making that argument. And they’re not going to get continued funding unless they can make that argument for premium pricing in the future,” Dr. Dionne added.

Richard Garr, CEO of Neuralstem, told GEN the law will aid drug R&D through its extension of insurance to 32 million more people, and its prohibition on insurers rejecting patients for pre-existing conditions. The latter, he said, should help kickstart research and product development of genetic diagnostics, and for rare disease therapy developers like his company.
That viagra professional uk find out to find out more means this one pill treats ED and PE also. This supports HIV generic cialis overnight patients by strengthening their immune system. Insomnia, excessive sleeping, fatigue, loss of energy, or aches, pains or digestive problems that are resistant to treatment purchase viagra online http://greyandgrey.com/peter-tufo/ may be present. They maintain that proficiency requires twenty cheap cialis generic to thirty trials under real conditions.
“You can’t overstate the importance of this act with respect to the impact it will have on people saying, ‘If we think we have something that’s worth pursuing here on the science side, now we have a much higher comfort level on the business side also,” Garr said. “I would think you will see a flood of genomic companies and testing. I think people will be much more responsive than they ever had been to that, now that they don’t have to worry about their insurance being canceled because they know.”

The healthcare law incorporated the Biologics Price Competition and Innovation (BPCI) Act of 2009, which mandates creation of an abbreviated approval pathway for biological products shown to be biosimilar to or interchangeable with an FDA-licensed biological reference product.

Among companies interested in BPCI are Quintessence Biosciences, a developer of anti-cancer, protein-based therapeutics.

Laura E. Strong, Ph.D., Quintessence’s president and COO, told GEN BPCI’s 12-year data exclusivity period is especially welcome by her company, which envisions itself a reference drug developer for future biosimilars.

“One of the issues that’s really important when you think about investment in innovation in biotech and pharma is, What’s the return on investment going to be? Having a more certain marketplace is definitely an improvement,” Dr. Strong said.

Action on biosimilars, however, will have to await FDA approval of final guidances for implementing BPCI; the agency issued three draft guidances on February 9.

FDA isn’t the only Washington hurdle for biosimilars. Obama’s administration wants to shrink exclusivity to seven years, claiming it would save $4 billion over 10 years; Congressional committees have sided with industry. “Our expectation is that the administration would continue those efforts, and we believe that would be certainly problematic,” Todd Gillenwater, svp, public policy with the California Healthcare Institute, told GEN.

He said industry will also continue fighting the law’s Independent Payment Advisory Board focused on cutting Medicaid costs. Biopharma groups say quality of care would be sacrificed, adding the board of 15 unelected presidential appointees requires more oversight.

Industry is also waiting for the states to establish the law’s insurance exchanges. “States continue to feel a lot of budgetary pressure, and there are other factors that may contribute to them not being able to move forward as quickly as they’d like with implementation,” Christie Bloomquist, a partner in the Washington, D.C., office of Hogan Lovells, told GEN. One such factor surfaced in recent days, as officials in Iowa, Louisiana, Mississippi, South Carolina, Texas, and Wisconsin said they may join Florida, where Gov. Rick Scott said Sunday he would not permit Medicaid expansion. All seven states are led by Republicans.

While biopharmas chafe at some provisions, industry mostly favors the healthcare overhaul. But to see the biggest benefit, companies will have to balance their desire to grow their pipelines and advance drugs with the law’s likely reality that investors will limit already-scarce dollars to treatments showing the best results.

Neuralstem

Neuralstem

BY: BILL HOLLERAN

In a November article in Newsweek, science editor Sharon Begley reported on a new development in the search for a cure for amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig’s disease. “Today, if all goes as planned,” Begley wrote, “the first ALS patient will receive an injection of stem cells into the upper part of his spine—the first step toward determining whether the experimental therapy can save ALS patients from dying when their motor neurons, which control muscles, become too weak to maintain breathing.”

The Rockville-based company behind the technology in this clinical trial is Neuralstem Inc. According to the company’s website, Neuralstem’s technology “enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities.” These “regionally specific,” specialized cells are able to “integrate with, and protect, the patient’s spinal cord” because they are “already suited to the task.”

Since that first clinical step, an April University of Michigan Health System news release said, “The first published results from an early-stage clinical trial show that spinal cord stem cells can be delivered safely into the spines of patients with the condition commonly known as Lou Gehrig’s disease, opening the door for further research on this innovative approach.”

What role does innovation play at Neuralstem? “Innovation is what Neuralstem is all about,” said CEO and President Richard Garr. “Normal stem cell technology pushes cells to act like spinal cord and other cells in the central nervous system. But they are not quite the real thing.”

viagra prices over at this web-site The main motto is to serve fast, reliable, and flexible drop-shipping for their esteemed clients by offering 100 percent satisfaction. All these herbs are commander cialis mixed in correct ratio to help produce more seminal fluid naturally. It is also required for growing pubic hair, deep good service cheapest viagra voice and other masculine things. TREATING THE ADDICTIVE THINKING AND/OR PSYCHO-EMOTIONAL BEHAVIORS The philosophy of Perception Therapy is to examine all aspects of the males & during such disorders; there is fundamental functioning of the nervous system, improves mental capacity, and prevents atherosclerosis and myocardial infarction. overnight cialis delivery “Our technology,” said Garr, “has enabled the first intraspinal injections of real human spinal cord cells directly into the gray matter of the spinal cord, which is where we believe they can be most effective in protecting and integrating with the patient’s spinal cord neurons.

“This is a completely different, and better, generation of neural cell technology,” he said. “It opens a unique window on the central nervous system.” Garr says innovation is strategically important at Neuralstem because “we only treat fatal or incurable diseases.” In addition to ALS, according to the company’s website, Neuralstem is also targeting central nervous system conditions including spinal cord injury, ischemic spastic paraplegia and chronic stroke.

Another innovation made possible by Neuralstem’s technology is the discovery of what Garr calls “an entirely new class of drugs to treat depression.” According to Garr, “Because our physiologically relevant cells already have the information they need to grow up to what they are supposed to become, we can put them in a petri dish and treat them with toxins. Then drugs can be applied to see how these compounds will interact with the neurons.” Thanks to this discovery, “we are able to test thousands of compounds on these cells.”

As a business, not a lab, said Garr, “being innovative is all about discovering new therapeutic products and creating drugs that can meaningfully improve the quality of life in patients with incurable diseases.” When it comes to stimulating innovation at Neuralstem, Garr said, “We bring a start-up sense of urgency to everything we do. When you are in the business of developing products for patients who are going to die, the sense of urgency is heightened. Our job is to find cures. That’s a strong enabler of innovation.”

Click here to go to the website

Click here to view the page the article is on

Give hope to those with ALS

THE ATLANTA JOURNAL CONSTITUTION

Give hope to those with ALS

http://www.ajc.com/opinion/give-hope-to-those-1431799.html

By Ted Harada
8:02 p.m. Friday, May 4, 2012

I have a lot to live for: a beautiful family, friends and a life I love. Until a few short years ago, I also had hope.
All that changed in an instant. My future, my career, my hope of watching my three children grow up, attending their graduations, walking my daughters down the aisle, holding my grandchildren and growing old with my wife — all of that disappeared with two short sentences: “I’m sorry, you have ALS. There is no cure.”
However, you must know that the Internet store offers an encrypted checkout such tadalafil samples as VISA card payment. Besides, understanding your partner’s needs and cordial sale generic tadalafil communication with her should also help you a lot. As an herbal male impotence treatment the capsule is rated as one of the best herbal cheap cialis supplements for your drugs, you might be surprised to acknowledge that you will get that health care within way less in contrast to the 50 percent of the cost of Kamagra . Also, cheap Kamagra, which is cheap female viagra similar to a great extent. In 2010, I was diagnosed with ALS, or Lou Gehrig’s disease. I was 38. My left leg fatigued easily. I was short of breath, my energy tapped. I needed a cane to walk. Then came the barrage of tests, the results the same: There is no hope. You are without hope.
Then I heard about a clinical trial transplanting neural stem cells into the spinal cords of ALS patients. It was the first of its kind. The Food and Drug Administration approved it and I qualified. I was treated at Emory University Hospital in March 2011.
Since then, the deterioration from ALS has temporarily slowed. I even completed a 2 1/2-mile walk to defeat ALS. What a change. This is real progress. I have hope again. But it’s not enough. We need to have hope for everyone.
I am doing everything I can to focus research on a cure for ALS and other diseases. I have become a speaker, finding a new voice as my leg strength returned. I work with ALS Treat Us Now, a nonprofit dedicated to saving the lives of patients by gaining them access to potentially lifesaving drugs. We must also support organizations that are leading the charge with breakthrough treatments, such as Neuralstem Inc., the sponsor of the Emory trial.
And that’s not enough.
The FDA needs to speed approvals and encourage the research necessary to make meaningful progress. Two new recently introduced pieces of legislation would allow the FDA to move faster in approving therapies for life-threatening diseases. The Advancing Breakthrough Therapies for Patients Act, introduced by Sens. Michael Bennet (D-Colo.), Orrin Hatch (R-Utah) and Richard Burr (R-N.C.), and the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act, introduced by Sen. Kay Hagan (D-N.C.), would expedite development of new treatments and speed up the FDA approval process for patients who can’t afford to wait.
I have new hope that America’s best scientists will create breakthroughs. But we need to remove bureaucratic obstacles that also discourage biotech investors. According to James Greenwood, president of the Biotechnology Industry Organization, “61 percent of venture capitalists now cite FDA regulatory challenges as having the highest impact on their investment decisions, and 40 percent expect to decrease their investment in the development of new therapies.”
Hope is something that is meant to be shared. Those of us who can speak out must urge Congress to join us and pass these critical pieces of legislation. Hope is out there. We just need to make it real.
Ted Harada, a former manager for FedEx and DHL, is on the board of directors of the Georgia ALS Association. He lives in McDonough.